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IDO2 is a relative of IDO1 implicated in tryptophan catabolism and immune modulation but
its specific contributions to normal physiology and pathophysiology are not known. Evolu-
tionary genetic studies suggest that IDO2 has a unique function ancestral to IDO1. In mice,
IDO2 gene deletion does not appreciably affect embryonic development or hematopoiesis,
but it leads to defects in allergic or autoimmune responses and in the ability of IDO1 to influ-
ence the generation of T regulatory cells. Gene expression studies indicate that IDO2 is a
basally and more narrowly expressed gene than IDO1 and that IDO2 is uniquely regulated
by AhR, which serves as a physiological receptor for the tryptophan catabolite kynurenine.
In the established KRN transgenic mouse model of rheumatoid arthritis, where IDO1 gene
deletion has no effect, IDO2 deletion selectively blunts responses to autoantigen but has
no effect on responses to neoantigen challenge. In human populations, natural variations
in IDO2 gene sequence that attenuate enzymatic activity have been reported to influence
brain cancer control and adaptive immune responses to the IDO2 protein itself, consistent
with the concept that IDO2 is involved in shaping immune tolerance in human beings.
Biochemical and pharmacological studies provide further evidence of differences in IDO2
enzymology and function relative to IDO1. We suggest that IDO2 may act in a distinct man-
ner from IDO1 as a set-point for tolerance to “altered-self” antigens along the self-non-self
continuum where immune challenges from cancer and autoimmunity may arise.
Keywords: indoleamine dioxygenase, tolerance, kynurenine pathway, aryl hydrocarbon receptor, autoimmunity,
rheumatoid arthritis
INTRODUCTION
Of the four tryptophan catabolic enzymes in mammals, IDO2 is
the most recently discovered and like the others (IDO1, TDO2,
and TPH1), it is implicated in immune control. While all the
three dioxygenases in this group (IDO1, IDO2, and TDO2) gen-
erate kynurenine as a product, TDO2 represents a structurally
distinct multimeric enzyme of divergent origin compared to the
monomeric IDO1 and IDO2 enzymes, which are related. The
human IDO2 gene is located downstream of IDO1 on chromo-
some 8p21 and these two genes bear close structural and evo-
lutionary relationships. Compared to the other enzymes, IDO2
expression is confined mainly to antigen-presenting immune cells,
liver, kidney, brain, and placenta, displaying a unique and relatively
more restricted pattern that is consistent with a non-redundant
function(s). Early studies of the physiological function of IDO1 by
Munn, Mellor, and colleagues pioneered the concept that trypto-
phan catabolism modulates immunity, based on the discovery that
a simple tryptophan mimetic, the IDO inhibitor D,L-1-methyl-
tryptophan (1MT), could trigger rejection of allogeneic murine
concept (1, 2). Subsequent to this discovery, 1MT has been used
in thousands of studies to study IDO function in diverse set-
tings of immune control. However, interpreting these studies may
be impacted by the discovery of IDO2, which under various
conditions has been found to be inhibited by 1MT like IDO1
(3–7). Thus, while 1MT has been used widely to implicate trypto-
phan catabolism in numerous chronic inflammatory pathologies,
such as cancer, chronic infection, allergy, neurological disorders,
and autoimmunity (8, 9), the possible contributions of IDO2 in
interpreting the effects of 1MT may be impactful. Another fine
review on IDO2 has appeared recently (10). This review summa-
rizes existing knowledge about IDO2 and its functions in immune
control and disease.
IDO2 DISCOVERY
IDO2 was discovered independently by groups working in the
areas of infectious disease, cancer research, and genomics (3,
11, 12). Ball et al. cloned IDO2 by searching cDNA libraries
used in high-throughput sequencing for IDO1-like sequences,
identifying in this manner a novel gene they termed INDOL1
(11). Recombinant enzyme was shown to catabolize tryptophan
to kynurenine like IDO1 but with a reduced relative activity.
Comparative genomics provided evidence that IDO2 arose by
gene duplication before the origin of the tetrapods. Expression
was documented in kidney, liver, and epididymis, localizing the
endogenous IDO2 enzyme to kidney tubular cells and spermato-
zoa. Distinct functions were suggested by differences in the cat-
alytic expression patterns noted within tissues and during malaria
infection.
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Metz et al. cloned IDO2 on the basis of partial IDO1 struc-
tural homologies that were found downstream of the human
IDO1 gene in a region of chromosome 8p12 that was misanno-
tated in early genome compilations (3). This work documented
the tryptophan catalytic activity of mouse and human cDNAs,
with the mouse isoform exhibiting higher catabolic activity but
both isoforms showing less activity compared to IDO1 under sim-
ilar conditions. Two single nucleotide polymorphisms (SNP) were
described in the IDO2 coding region that were widely distributed
in human populations, R248W and Y359X, each of which atten-
uated catalytic activity. A narrow range of IDO2 expression was
documented by mouse tissue analysis with highest expression in
liver, kidney, and placenta. Complex RNA splicing patterns were
revealed in placenta and brain. In human, 293 cells engineered
to overexpress IDO1 and IDO2, there were differences in how
tryptophan depletion mediated by each enzyme affected transla-
tion by regulating eIF2α, with IDO2-expressing cells unresponsive
to subsequent tryptophan restoration suggestive of a pseudo-
differentiation effect. Moreover, IDO2-expressing cells exhibited
a unique susceptibility to catalytic inhibition by the D isoform of
1MT, which selectively impeded the activity of full-length IDO2
but not IDO1 in this setting (3).
Yuasa et al. described a novel mouse IDO2 cDNA identified
as an IDO1 paralog in a set of several evolutionary studies of
IDO genes that supported the concept of IDO2 functional differ-
ences (12). Characterizing the activity of the recombinant mouse
enzyme, they noted the relatively lower tryptophan catabolic activ-
ity of IDO2 compared to IDO1-like Ball et al. and Metz et al.
Based on a phylogenetic analysis, they argued that IDO2 and other
low-activity IDO paralogs from non-mammalian organisms were
proto-IDO enzymes (12). Interestingly, while IDO-like genes were
observed in several lower vertebrates, the genomes from chicken
and zebrafish exhibited only one IDO-related gene most similar
to IDO2. Accordingly, they argued that IDO1 may have arisen
by gene duplication of a more ancient proto-IDO gene before
the divergence of marsupial and eutherian (placental) mammals.
Given the relatively weaker catalytic activity of IDO2 enzymes, this
group suggested that L-Trp may not be a true in vivo physiolog-
ical substrate, although methylene blue rather than physiological
reductants (used by all groups in the oxygenase reactions stud-
ied) might not provide reliable insights into function, as noted
in Ref. (6). This intriguing suggestion is consistent with the find-
ing of Metz et al., who found that IDO2-overexpressing human
293 cells were unresponsive to tryptophan restoration after tryp-
tophan had been depleted in cell culture by IDO2 activity, in
stark contrast to IDO1-overexpressing cells, which responded
fully.
A subsequent study of fungal IDO homologs by this group fur-
ther corroborated the hypothesis that IDO2 functions in some
unique manner (13). Specifically, this work revealed that the
tryptophan catabolic activity of some fungal IDO enzymes was
sufficient to supply nicotinamide adenine dinucleotide (NAD),
the downstream end product of the kynurenine pathway, whereas
other fungal IDO enzymes lacked sufficient tryptophan catabolic
activity to supply NAD. Thus, it seems clear that low catalytic
efficiency IDO enzymes are only conserved in evolution, but that
they also diverged from active IDO enzymes at early times. Overall,
initial characterization of IDO2 suggested features arguing for a
unique functional role(s) relative to IDO1.
IDO2 EXPRESSION PATTERNS
Several studies have described expression patterns of IDO2 mes-
sage and protein that suggest unique regulation but also some
functional redundancy with IDO1. Whereas IDO1 predominates
in colon and epididymis, IDO2 mRNA predominates in cerebral
cortex, liver, and kidney. Evidence of redundancy is suggested by
the finding that Ido1 genetic deficiency in mice leads to com-
pensatory upregulation of IDO2 in the epididymis, where IDO1
is relatively more highly expressed normally (14). IDO2 is also
expressed like IDO1 in antigen-presenting cells but under some-
what different control. The IDO2 promoter includes a prominent
binding site for the transcription factor IRF-7, a master regula-
tor of dendritic cell maturation, suggesting a central role in these
professional antigen-presenting cells (15). In this setting, IDO2
appears to be a mainly basally expressed gene, the levels of which
vary little by comparison to IDO1 levels that are more robustly reg-
ulated. Current information suggests that at the RNA level IDO2
expression is regulated by various pro-inflammatory stimuli, but
less robustly than IDO1, including in dendritic cells by interferon-
γ (IFN-γ), IL-10, lipopolysaccharide, and prostaglandin E2 (3,
15–18). Interestingly, activation of the aryl hydrocarbon receptor
(AhR), a transcription factor, which can serve as a physiologi-
cal ligand for kynurenine (19), has been reported to upregulate
IDO2 in dendritic cells (20, 21). Since activated IDO1 generates
kynurenine, this observation presents the intriguing possibility
of a downstream mechanism to elevate IDO2 levels in dendritic
cells where IDO1 becomes upregulated, a prospect discussed fur-
ther below. IDO2 has been reported to be overexpressed along
with IDO1 in pancreatic cancer (22, 23), and in basal cell skin
carcinomas, where its expression appears to be driven by the T-
cell-attracting chemokine CXCL11 (16), but neither the extent of
IDO2 expression nor knowledge of its regulatory mechanisms in
cancer settings are as widely described as IDO1 as yet.
MOUSE GENETIC STUDIES: IDO2 IS CRITICAL FOR
IDO1-DEPENDENT Treg GENERATION
Our group constructed and characterized mice that are geneti-
cally deficient in Ido2 to investigate its functions in development,
normal physiology, and pathophysiology (24). These mice retain
the normal structure and expression of the nearby upstream Ido1
gene. Interest in generating this strain was reinforced by our dis-
covery that IDO2 RNA levels were attenuated in myeloid cells from
Ido1−/− mice due to an altered RNA splicing event that abolishes
catalytic function (24). This was a tissue-specific effect insofar as
IDO2 RNA splicing was unaffected in livers from Ido1−/− mice.
How IDO1 may affect IDO2 RNA processing was unclear but
likely to be indirect. Nevertheless, it appeared that in addition to
their deficiency in IDO1 function Ido1−/− mice were also mosaic
deficient for IDO2 function. This revelation was important since
it influences the interpretation of phenotypic results involving
myeloid cells from Ido1−/−mice, widely studied in the field, which
might conceivably be explained by loss of function in IDO2 rather
than IDO1. Indeed, the possibility of an IDO1→ IDO2 genetic
pathway in myeloid cells was consistent with expression data from
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Bankati et al., who had found that activation of the kynurenine-
stimulated transcription factor AhR was sufficient to stimulate
IDO2 transcription (21). Overall, we reasoned that mice deficient
in IDO2 might not only help define its functions but also help
re-interpret of functions previously ascribed to IDO1 (made on
the basis of findings from Ido1−/− mice).
IDO1 acts to control the activation and differentiation of T
regulatory cells (Treg) in a variety of settings, including cancer
(25–27). Given evidence of genetic epistasis between IDO1 and
IDO2, we asked whether IDO2 loss could affect IDO1-mediated
Treg generation in settings where an essential function for IDO1
has been established. In WT or Ido2−/− mice treated with CpG
oligonucleotides, a critical role for IDO2 in Treg generation was
documented in an established T-cell suppression assay (26). Sup-
pression relieved by Ido2 loss in this assay was reversed by a cocktail
of PD1 and PD-L1/PD-L2 antibodies that block PD-1 interac-
tion with PD-L1/PD-L2, a hallmark of IDO1-activated Tregs (26).
Strikingly, the effect observed phenocopied the effects of Ido1 loss
in Treg cells generated under the same conditions, directly sup-
porting a functional requirement for IDO2 in Treg generation and
offering further evidence of its genetic epistatic interaction with
IDO1.
Comparing the response of Ido2-deficient mice in a classi-
cal assay for contact hypersensitivity led to further support for
a role of IDO2 in T-cell-dependent immune responses (24). While
Ido1−/− and Ido2−/− mice both displayed a reduction in con-
tact hypersensitivity, relative to WT control animals, loss of Ido2
but not Ido1 was associated with a reduction in systemic levels
of cytokines implicated causally in this classical immune response
(GM-CSF, G-CSF, IFN-γ, TNF-α, IL-6, and CCL2). Reductions
in GM-CSF might be relevant in skin, given its critical role in
stimulating AhR-dependent maturation of Langerhans cells (LC)
(28), which are thought to be involved in skin tolerance. Since
IDO2 is itself an AhR target gene (20, 21), one plausible model
is that IDO2 acts downstream of AhR to support local expression
of GM-CSF, thereby promoting LC maturation and LC-mediated
tolerance through an autocrine loop. While focused mechanistic
investigations are needed such models may offer a logical starting
point to interpret how IDO2 may act in antigen-presenting cells
to influence T-cell function.
Distinct contributions to pathogenic inflammatory processes
were likewise indicated in skin carcinogenesis assays, where tumors
are induced by a single topical administration of the Ras muta-
gen DMBA followed by chronic weekly exposure to the pro-
inflammatory phorbol ester TPA. Here, while Ido1 loss was suffi-
cient to blunt tumor formation, as observed previously (29), Ido2
loss had no effect on the susceptibility to either formation or pro-
gression of tumors (24). Taken together, these results offered the
first direct physiological evidence that IDO2 helps regulate adap-
tive immunity, perhaps through contributions to inflammatory
control that are at least partly non-redundant with IDO1.
MOUSE GENETIC STUDIES: IDO2 IS CRITICAL FOR
AUTOANTIBODY PRODUCTION AND AUTOIMMUNITY
Rheumatoid arthritis (RA) is an autoimmune disorder that has
been associated with aberrant IDO activity and defective T-cell
function (30–32). In IDO studies conducted in preclinical mouse
models of RA, there is complexity in interpreting the contributions
of IDO to the disease state, with opposing effects depending on
the model used. Nevertheless, as an initial assessment of the possi-
ble connections between IDO2 and T-cell function in a genetically
defined model, we compared the effects of genetic deletion of
IDO1 or IDO2 in the KRN transgenic mouse model of sponta-
neous RA. The specific pathophysiological relevancy of the KRN
model to human disease is justified in part by its mimicry of the
elevated tryptophan degradation in RA patients, which has been
appreciated clinically for many years [as summarized in Ref. (33)].
In the KRN model of spontaneous RA, we found that IDO2 was
crucial for the development of arthritis but that IDO1 was com-
pletely dispensable. This finding was provocative in light of earlier
observations that D-1MT treatment could attenuate RA in this
model (34) and that D-1MT was capable of inhibiting the tryp-
tophan catabolic activity of IDO2 but not IDO1 in human cells
(3). Interestingly,while Ido2 deficiency phenocopied D-1MT treat-
ment, Ido1 deficiency abolished responses to D-1MT even though
Ido1 was dispensable for RA pathogenicity, providing further
support for IDO1-IDO2 genetic interaction in immune control.
Investigations of cellular mechanisms revealed that the
decreased joint inflammation displayed by Ido2−/− mice rela-
tive to control animals was due to a reduction in pathogenic
autoantibodies and antibody-secreting B cells. Strikingly, reduced
inflammation in Ido2−/− mice was associated with a defect in the
initiation of autoreactive B cell responses, but not with any overall
defect in normal B cell responses: total serum immunoglobu-
lin levels were unaffected in Ido2−/− mice, and those mice were
fully competent to mount productive antibody responses to model
antigens in vitro and in vivo. Ido2 deficiency also reduced CD4+
helper T-cell responses; however, in this case reciprocal adoptive
cell transfer studies showed that this defect was extrinsic to T cells.
While interpretation of these results must be tempered in light of
distinct effects of IDO signaling in collagen-induced models of
arthritis (35), a different preclinical model used in the field, our
genetic studies of IDO2 in the mouse nevertheless offer the first
direct evidence that it makes unique contributions to the control
of adaptive immunity and inflammatory disease.
IDO2 IN HUMAN STUDIES
In human immune physiology, the implication of a genetic linkage
between IDO1 and IDO2 is intriguing in light of the broad distri-
bution of two functionally attenuating SNP in the coding region
of the IDO2 gene in human populations (3). These SNP varia-
tions dramatically reduce or abolish tryptophan catabolic activity,
therefore varying the level of this IDO2 function in different indi-
viduals, perhaps affecting T-cell-dependent immune control as a
result. Since antigen-presenting cells are a primary site of IDO2
expression, further investigation is needed to understand how
IDO2 may act to initiate, maintain, fix, or reverse antigen toler-
ance. Along these lines, a recent study in human DC suggests that
IDO2 may help fix basal levels of tolerance, acting differently than
IDO1, which unlike IDO2 is induced strongly by prostaglandin
E2 (PGE2) and other pro-inflammatory signals in these cells (15).
This study compared the patterns of expression and regulation
of IDO1 and IDO2 in human circulating DC. At the protein
level, IDO1 was expressed only in circulating myeloid DC and was
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modulated by PGE2, whereas IDO2 was expressed in both mDC
and plasmacytoid DC and was not modulated by PGE2. In circu-
lating DC from healthy subjects, IDO1 expression relied on PGE2
whereas IDO2 expression was constitutive. However, in DC from
arthritis patients, circulating DC expressed both IDO1 and IDO2.
Notably, mDC and plasmacytoid DC both generated T regulatory
cells through a mechanism that relied upon both IDO1 and IDO2
expression, based on the interpretation of RNAi-mediated gene
silencing experiments (15). These observations further supported
a model for IDO1-IDO2 genetic interaction in antigen-presenting
cells. Further, they suggested that IDO2 may act as a downstream
basal function in determining “set points” for tolerance deter-
mined by IDO1 acting as an upstream inducible function. In any
case, this work established that IDO2 is expressed stably in DC
under steady-state conditions and that it may contribute to the
homeostatic tolerogenic capacity of DC.
The relatively small number of studies of IDO2 in human
systems has focused on cancer and where roles in immunosuppres-
sion have been hypothesized. In evaluating the use of IDO2 SNP as
biomarkers for therapeutic response, Eldredge et al. stratified the
response of brain metastasis patients to whole brain radiotherapy
(WBRT) when they were orally administered low-dose chloro-
quine concomitant with therapy (36). This experiment was based
on a multipronged rationale. First, patients with brain malig-
nancy who received WBRT were in some cases found to benefit
significantly from low-dose chloroquine when administered con-
comitant with therapy (37). Second, low-dose chloroquine was
serendipitously discovered to indirectly inhibit the tryptophan
catabolic activity of IDO2 but not IDO1 in cells, apparently by
selective interference with the physiologic reductant used by each
enzyme in the oxygenase reaction (R. Metz, unpublished obser-
vations). Third, the possibility that IDO2 might contribute to
cancer immunosuppression in some settings where it is expressed,
including brain, similar to the manner in which IDO1 has been
implicated widely (9). Fourth, that IDO2 inhibition might relieve
immunosuppression in such settings, but only in patients with
a functionally active SNP configuration in their IDO2 genes.
In a prospective, single-cohort study, WBRT (37.5 Gy in 2.5 Gy
daily fractions) administered with concurrent CQ (p.o. 250 mg
daily) was safely tolerated in patients with newly diagnosed brain
metastases from biopsy-proven, primary lung, breast, or ovar-
ian tumors (n= 20). The main finding of this study was a trend
toward increased overall survival in patients with wild-type IDO2
compared to patients with heterozygous or homozygous SNP con-
figurations that ablate IDO2 enzyme activity (10.4 vs. 4.1 months;
p= 0.07). In light of evidence that tryptophan catabolism in the
brain may influence affective disorders (i.e., mood), it is inter-
esting that a recent study also showed a trend in association of
IDO2 region SNP in predicting outcomes to treatment with the
anti-depressant drug citalopram (Celexa®) (38).
Additional studies encourage the notion that IDO2 may offer
some pathogenic support to advanced cancer in certain settings,
albeit less widely than IDO1. In cancer, there are reports of IDO2
overexpression in certain gastrointestinal tumors (39), including
frequent overexpression in pancreatic cancer (23). Although there
is little exploration of this direction as yet, one study reported
that skin administration of IDO2 siRNA was as efficient as IDO1
siRNA in promoting the efficacy of a HER2-based DNA vac-
cine, in a mouse model of breast cancer (40). In a different and
more provocative direction, Sorensen et al. have described nat-
urally occurring anti-IDO2 immune responses in the peripheral
blood of both cancer patients and healthy donors, specifically, in
the presence of a spontaneous cytotoxic T-cell reactivity directed
against the IDO2 protein that can recognize and destroy human
tumor cells (39). This work extends an earlier description from
the same group of a similar parallel response directed against the
IDO1 protein (41). More recent work on the IDO2 response strat-
ified the number of responses based on the IDO2 coding region
SNP, highlighting stronger responses to homozygous Y359 alle-
les that do not truncate the IDO2 protein, and more numerous
responses to homozygous 248W alleles that reduce tryptophan
catabolic activity relative to the wild-type 248R configuration (42).
Thus, IDO2 SNP allelic status, which affects tryptophan catalytic
function, appears to influence a self-reactive cytotoxic T-cell-
dependent response that is directed against IDO2 protein. The role
of IDO1 and IDO2 in cytotoxic T-cell responses directed against
self has been reviewed recently with a perspective on regulating
this response in the setting of cancer therapy (43).
IDO2 BIOCHEMISTRY AND PHARMACOLOGY
Much of the existing literature on IDO2 relates to questions about
its biochemical and signaling properties and a budding interest in
its pharmacologic inhibition for therapeutic purpose. As alluded
to above, there is a general consensus that the tryptophan cata-
bolic activity of IDO2 and IDO2-like genes in non-mammalian
organisms is much weaker than IDO1. Studies of the mouse IDO2
enzyme show it to be more catalytically active than the human
enzyme, which is quite weak indeed, yet even in mice genetic
knockout does not affect systemic kynurenine levels (i.e., as mea-
sured in blood serum) (24). Moreover, in cells where IDO2 or
IDO1 are overexpressed to levels that deplete tryptophan, induc-
ing autophagy as a result (44), restoring tryptophan is insufficient
to relieve protein translation blockades as monitored by a reversal
in the expression of the translation stress-induced transcription
factor LIP (3, 44), a pathway with pathophysiologic relevance to
IDO-driven cancer (45). All in all, the work to date has fed skep-
ticism that tryptophan is an important physiological substrate
for IDO2, as Yuasa et al. originally speculated (6). Supporting
this idea, three enzymologic studies comparing tryptophan-like
compounds as substrates and inhibitors have presented results
arguing that human IDO2 may be somewhat more promiscuous
than IDO1 (46–48). A screen of a library of FDA-approved drugs
for inhibitory activity against recombinant IDO2 identified the
proton pump drug tenatoprazole as a low-micromolar inhibitor
(IC50= 1.8µM), with no IDO1 or TDO2 inhibition up to 50-fold
higher drug levels (47). A comparison of recombinant proteins
extending the enzymological analysis of human IDO2 reinforced
its distinct nature from IDO1, in terms of substrate specificity and
affinity, and also based on the identification of tryptophan deriva-
tives that are mutually exclusive as substrates (48). Two groups
conducting modeling and experimental testing of novel IDO1
inhibitors demonstrated selectivity against murine IDO2, adding
to the evidence of enzymologic differences between IDO1 and
IDO2 (49, 50). Going forward, pressing questions to resolve are
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whether and where tryptophan may be physiologically relevant as
an IDO2 substrate, if at all, and whether there are non-tryptophan
substrates that are physiologically or pathophysiologically relevant
to IDO2 function, as a growing number of investigators seem to
currently suspect.
Several studies have addressed the inhibitory properties of 1MT
as an IDO2 inhibitor (5–7, 46, 48, 51), particularly with regard
to the racemic selectivity of D-1MT in whole cells as originally
reported by our group (3). This area of investigation continues
to be fraught not only with concerns about suitable physiological
substrates, as noted above, but also about suitable physiological
reductants involved in the oxygenase reaction(s) that can be medi-
ated by IDO2. We have discussed this issue recently at some length
elsewhere (9). Briefly, we have argued that use of methylene blue as
a non-physiological reductant obscures the core challenge of how
to interpret the ability of 1MT racemers to inhibit IDO2 activity in
cells where it may make relevant contributions to normal physiol-
ogy or pathophysiology, for example, in cancer or autoimmunity.
In exploring other reductants,Austin et al. employed cytochrome b
in oxygenase reactions of recombinant IDO2 but still found it less
active than IDO1 and poorly inhibited by either 1MT racemer (46).
In examining IDO2 contributions in a human T-cell system, Qian
et al. reported that IDO2 could suppress cell growth but that nei-
ther 1MT racemer exhibited potency in inhibiting this effect (4).
In Ido2-deficient mice, we found that genetic ablation of IDO2 but
not IDO1 could phenocopy the effect of D-1MT in the context of
the KRN model of RA autoimmunity (33, 34). This system offers
a murine setting where biochemical studies can be connected to a
genetic and pathobiological context, perhaps encouraging investi-
gations in a human setting that can rule in or rule out the relevancy
of 1MT as an IDO2 inhibitor. In closing, we propose that the use
of IDO2-deficient mice will be useful to advance studies of how
immunometabolism mediates tolerance in normal physiology and
disease; to gain mechanistic insights into how IDO pathways direct
pathogenic inflammation in diverse settings; and to help inform
clinical development of IDO and TDO inhibitors being devel-
oped to treat cancer and other inflammatory disorders, where early
clinical trials have suggested therapeutic promise.
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